GNH USA

Europe — EMA

Menquadfi

GNH USA supplies Menquadfi (Neisseria meningitidis), a vaccine for prevention of invasive disease caused by meningococcal serogroup C.

Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi

Request sourcing

1
Pack/s

What is Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi?

Neisseria meningitidis serogroup C polysaccharide conjugated to tetanus toxoid, the active ingredient in Menquadfi, is a vaccine presented as a powder for suspension for injection for intramuscular use. It induces immunity to prevent invasive disease caused by Neisseria meningitidis serogroup C in at‑risk individuals.

GNH USA supplies Menquadfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, travel clinics and public health programs worldwide.

What is Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi used for?

Menquadfi is used to prevent meningococcal disease caused by serogroup C, a bacterial infection that can lead to severe invasive illness.

- Invasive meningococcal disease (serogroup C): provides active immunity to prevent infection. - Outbreak control in communities: reduces transmission during serogroup C outbreaks. - Travelers to endemic regions: protects individuals traveling to areas with high serogroup C prevalence. - Adolescents and young adults: offers long‑lasting protection in age groups at increased risk.

What are the side effects of Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi?

Menquadfi may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness and swelling: localized erythema and edema. - Fever: low‑grade temperature rise within 24‑48 hours. - Headache: transient mild headache. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder with muscle weakness. - Seizures: infrequent occurrence of convulsive episodes. - Hypotension: sudden drop in blood pressure post‑vaccination.

What precautions apply to Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi?

Before administering Menquadfi, healthcare providers should observe several precautionary measures to ensure safety.

- Allergy assessment: avoid use in individuals with severe hypersensitivity to any vaccine component. - Pregnancy considerations: safety not established; weigh benefits against potential risks. - Immunocompromised patients: vaccine may elicit a reduced immune response. - Concomitant vaccines: separate administration from live vaccines by at least 4 weeks. - Blood product interaction: postpone immunoglobulin therapy for 4 weeks after vaccination. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi interact with?

Menquadfi can interact with certain medicines and vaccines, requiring attention to timing and monitoring.

Major Interactions (Avoid): - Live bacterial vaccines: should not be given concurrently; separate by at least 4 weeks. - Immunoglobulin products: avoid administration within 4 weeks before or after vaccination.

Moderate Interactions (Monitor Closely): - Other inactivated vaccines: may be co‑administered but monitor for increased reactogenicity. - Immunosuppressive therapy: may diminish vaccine‑induced immunity; assess antibody response. - Antipyretic agents: can mask fever, a common post‑vaccination sign; use judiciously.

Frequently asked questions

What is Menquadfi used for?+
Menquadfi is a conjugate vaccine indicated for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. It is administered to individuals at risk, including adolescents, travelers to endemic areas, and during outbreak control efforts.
How does the Neisseria meningitidis serogroup C conjugate work?+
The vaccine links the serogroup C capsular polysaccharide to tetanus toxoid, forming a protein‑polysaccharide conjugate. This structure engages T‑cells, prompting a strong B‑cell response that produces high‑affinity IgG antibodies and immunological memory against the serogroup C bacterium.
What is the usual dose of Menquadfi?+
The prescribed dose of Menquadfi is determined by the treating clinician. Typically, a single intramuscular injection is given, with booster doses recommended according to national immunization schedules or specific risk‑assessment guidelines.
Is Menquadfi safe during pregnancy or breastfeeding?+
Safety data for Menquadfi in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any unknown risks before vaccinating pregnant or breastfeeding individuals.
How do I order Menquadfi from GNH USA?+
To order Menquadfi, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.
How does Menquadfi compare with other meningococcal vaccines?+
Menquadfi is a serogroup C‑specific conjugate vaccine, whereas some alternatives cover multiple serogroups (A, C, W, Y, or B). The conjugate format offers T‑cell dependent immunity, which generally yields longer‑lasting protection and immunological memory compared with plain polysaccharide vaccines.
How should Menquadfi be stored and handled?+
Menquadfi must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the suspension before reconstitution and administration.
How is Menquadfi administered?+
The vaccine is supplied as a powder for suspension that is reconstituted with the provided diluent. After mixing, it is given as a single intramuscular injection, usually in the deltoid muscle, by a qualified healthcare professional.
What are the most serious risks to watch for with Menquadfi?+
Serious adverse events, although rare, include anaphylaxis, Guillain‑Barré syndrome, seizures, and severe hypotension. Immediate medical attention is required if any signs of a severe allergic reaction or neurological symptoms develop after vaccination.
Who should not receive Menquadfi?+
Individuals with a known severe allergy to any component of Menquadfi, including the tetanus toxoid carrier, should not receive the vaccine. Caution is also advised for those with uncontrolled immunodeficiency or who have experienced a severe reaction to a previous meningococcal vaccine.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi
Route
Intramuscular Use
Manufacturer
Sanofi Winthrop Industrie
Origin
EU